Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001866089 | SCV002235986 | pathogenic | Fanconi anemia complementation group O | 2022-06-23 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. RNA analysis performed to evaluate the impact of this premature translational stop signal on mRNA splicing indicates it does not significantly alter splicing (Invitae). ClinVar contains an entry for this variant (Variation ID: 1209850). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 32658311). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu303*) in the RAD51C gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD51C are known to be pathogenic (PMID: 20400964, 21990120, 24800917). |
Medical Genetics Laboratory, |
RCV001579300 | SCV001805834 | pathogenic | Breast carcinoma | 2021-08-21 | no assertion criteria provided | clinical testing | Invasive Breast Carcinoma grade III EST= - PRO = - HER2 = - KI = 50% |